Idera Pharmaceuticals, Inc. (IDRA) Research

Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide. This compound functions as a direct TLR9 agonist, designed to stimulate the immune system to combat solid tumors, specifically targeting head and neck squamous cell carcinoma and colorectal cancer. The firm also holds a strategic collaboration agreement with Bristol-Myers Squibb. Founded in 1989, Idera Pharmaceuticals, Inc. is headquartered in Exton, Pennsylvania.

Market snapshot

Symbol
IDRA
Price
$0.43
Day change
-23.04%
Market cap
$1.1M
P/E ratio
-0.06x
52-week range
0.4201-16.0
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allakos Inc. (ALLK)
  • Angion Biomedica Corp. (ANGN)
  • AnPac Bio-Medical Science Co., Ltd. (ANPC)
  • Freeline Therapeutics Holdings plc (FRLN)
  • Gemini Therapeutics, Inc. (GMTX)
  • Liminal BioSciences Inc. (LMNL)
  • LakeShore Biopharma Co., Ltd (LSB)
  • Marinus Pharmaceuticals, Inc. (MRNS)

Recent insider activity

  • GOWEN MAXINE — S-Sale (51 shares) on 2023-08-10
  • MILANO VINCENT — S-Sale (3283 shares) on 2023-08-10
  • Pillar Invest Corp — P-Purchase (26965 shares) on 2023-05-17
  • Pillar Invest Corp — S-Sale (3605 shares) on 2023-07-12
  • Pillar Invest Corp — S-Sale (2213 shares) on 2023-07-13

Open Idera Pharmaceuticals, Inc. (IDRA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.